- 作者: Chieh Yang, John Nguyen & Yun Yen
- 作者服務機構: 1.College of Medical Technology, Taipei Medical University, Taipei City, Taiwan 2.Covina Discovery Center, Theragent Inc., Covina, CA, USA 3.Department of Internal Medicine, School of Medicine, University of California Riverside, Riverside, CA, USA
- 中文摘要:
- 英文摘要:
Chimeric antigen receptor (CAR)-T cell therapies have been approved by FDA to treat relapsed or refractory hematological malignancies. However, the adverse effects of CAR-T cell therapies are complex and can be challenging to diagnose and treat. In this review, we summarize the major adverse events, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and CAR T-cell associated HLH (carHLH), and discuss their pathophysiology, symptoms, grading, and diagnosis systems, as well as management. In a future outlook, we also provide an overview of measures and modifications to CAR-T cells that are currently being explored to limit toxicity. - 中文關鍵字:
- 英文關鍵字: Chimeric antigen receptor (CAR)-T cell therapies, Cytokine release syndrome, Immune efector cellassociated neurotoxicity syndrome, Macrophage activation syndrome